slides · global inventory
All filtered slides
Global slide inventory for the active corpus filters, with each row opening the slide detail view.
Corpus coverage
319,975 slides
319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.
- Total slides
- 319,975
- Described
- 319,974
- Pending
- 1
100%ready for canon
Slide type composition
dynamicclickable
Slide type
Showing 319,974 described slides — 100.0% of 319,975 rendered pages
+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs
Tile area is proportional to slide count. Click a category to open its subtype map.
all document kinds · all orientations
Slide collection
12,211-12,240 of 319,975
32
Mergers and Acquisitions in LatAm: Evolution and prospectsMergers and Acquisitions in LatAm: Evolution and prospects · L.E.K.
Consulting deck Strategy consulting 1 hit
01
Perspectives on US Healthcare Inflation Insights from L.E.K. ConsultingPerspectives on US Healthcare Inflation Insights from L.E.K. Consulting · L.E.K. Consulting
Consulting deck Strategy consulting Beat · Situation & Context1 hit
02
Perspectives on US Healthcare Inflation Insights from L.E.K. ConsultingPerspectives on US Healthcare Inflation Insights from L.E.K. Consulting · L.E.K. Consulting
Consulting deck Strategy consulting Beat · Situation & Context1 hit
03
The chart uses a dual-line plot to show the divergence between healthcare and general inflation, with a shaded region for the Great Recession.Perspectives on US Healthcare Inflation Insights from L.E.K. Consulting · L.E.K. Consulting
Consulting deck Strategy consulting Beat · Problem & ComplicationLoop · Mece Breakdown1 hit
04
Data shows hospital-related services as the primary driver of recent healthcare inflation.Perspectives on US Healthcare Inflation Insights from L.E.K. Consulting · L.E.K. Consulting
Consulting deck Strategy consulting Beat · Problem & ComplicationLoop · Mece Breakdown1 hit
05
The chart uses a grouped bar structure to compare annual inflation trends across 12 specific healthcare sub-segments.Perspectives on US Healthcare Inflation Insights from L.E.K. Consulting · L.E.K. Consulting
Consulting deck Strategy consulting Beat · Problem & ComplicationLoop · Mece Breakdown1 hit
06
The slide uses a dual-axis chart combining line graphs for cumulative change and bar charts for 12-month percentage change.Perspectives on US Healthcare Inflation Insights from L.E.K. Consulting · L.E.K. Consulting
Consulting deck Strategy consulting Beat · Evidence & Proof1 hit
07
The slide uses a side-by-side comparison framework to contrast opposing economic forces.Perspectives on US Healthcare Inflation Insights from L.E.K. Consulting · L.E.K. Consulting
Consulting deck Strategy consulting Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
08
The chart highlights a divergence between healthcare inflation and general inflation, with a specific forecast range for healthcare.Perspectives on US Healthcare Inflation Insights from L.E.K. Consulting · L.E.K. Consulting
Consulting deck Strategy consulting Beat · Impact & Next StepsLoop · Cost Of Inaction1 hit
09
The slide uses a vertical arrow to indicate a progression from 'Nearer-term/Lower potential impact' to 'Longer-term/Greater potential impact'.Perspectives on US Healthcare Inflation Insights from L.E.K. Consulting · L.E.K. Consulting
Consulting deck Strategy consulting Beat · Impact & Next StepsLoop · Cost Of Inaction1 hit
10
The slide uses a vertical arrow to indicate a progression from 'Nearer-term/Lower potential impact' to 'Longer-term/Greater potential impact'.Perspectives on US Healthcare Inflation Insights from L.E.K. Consulting · L.E.K. Consulting
Consulting deck Strategy consulting Beat · Impact & Next StepsLoop · Cost Of Inaction1 hit
11
The slide uses a vertical arrow to indicate a progression from 'Nearer-term/Lower potential impact' to 'Longer-term/Greater potential impact'.Perspectives on US Healthcare Inflation Insights from L.E.K. Consulting · L.E.K. Consulting
Consulting deck Strategy consulting Beat · Solution & Approach1 hit
12
Perspectives on US Healthcare Inflation Insights from L.E.K. ConsultingPerspectives on US Healthcare Inflation Insights from L.E.K. Consulting · L.E.K. Consulting
Consulting deck Strategy consulting 1 hit
01
Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development ReportPivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting Beat · Situation & Context1 hit
02
Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development ReportPivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting Beat · Situation & Context1 hit
03
Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development ReportPivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting Beat · Situation & Context1 hit
04
Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development ReportPivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting Beat · Situation & Context1 hit
05
The table is segmented into three thematic blocks: demographics, economic indicators, and healthcare market metrics.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting Beat · Situation & Context1 hit
06
Uses a PEST framework (Policy, Economy, Society, Technology) to structure the market analysis.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting Beat · Problem & Complication1 hit
07
The slide uses a comparative bar chart structure to contrast high growth in China (29% CAGR) against stable growth in the U.S. (3% CAGR).Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting Beat · Problem & Complication1 hit
08
The slide uses a honeycomb layout to group regulatory initiatives. Color coding indicates the nature of the policy (R&D, Registration, Pricing/Market Access, Commercialization).Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting Beat · Problem & Complication1 hit
09
The slide uses stacked bar charts to show the composition of clinical trials by phase (I, II, III) for China and the US.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting Beat · Problem & Complication1 hit
10
Data refers to enterprises above designated annual revenue size (>20M RMB). Exchange rate 6.25 used.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting Beat · Problem & Complication1 hit
11
Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development ReportPivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting Beat · Problem & ComplicationLoop · Cost Of Inaction1 hit
12
The slide combines quantitative survey data (N=101) with qualitative expert quotes to contextualize the market sentiment.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting Beat · Solution & ApproachLoop · Cost Of Inaction1 hit
13
Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development ReportPivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting Beat · Solution & ApproachLoop · Cost Of Inaction1 hit
14
Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development ReportPivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting Beat · Solution & ApproachLoop · Cost Of Inaction1 hit
15
Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development ReportPivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting Beat · Solution & ApproachLoop · Cost Of Inaction1 hit
16
The chart uses a broken y-axis to accommodate the large number of companies in the 1-5 project range.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting Beat · Solution & ApproachLoop · Cost Of Inaction1 hit
17
The chart displays 4 categories of FDA designations with stacked segments representing product types.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting Beat · Solution & ApproachLoop · Cost Of Inaction1 hit